Mirikizumab for Inflammatory Bowel Disease

This trial evaluates how well mirikizumab works for individuals with inflammatory bowel disease (IBD), specifically ulcerative colitis or Crohn's disease. It seeks to determine if mirikizumab reduces the need for increased medical care, such as additional doctor visits or hospital stays, compared to other standard treatments. Participants will receive either mirikizumab or another biologic therapy while maintaining their usual healthcare routine. This study suits adults who have tried other IBD treatments and have not previously used mirikizumab. As a Phase 4 trial, the research focuses on understanding how mirikizumab, an FDA-approved and effective treatment, can benefit more patients.

The trial information does not specify if you need to stop your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that mirikizumab is generally well-tolerated for treating inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. In earlier studies, only 5.2% of patients experienced serious side effects, and just 2.8% discontinued treatment due to these effects. This indicates that most patients handle the treatment well.

Long-term research indicates that mirikizumab remains safe even after four years of use, maintaining a stable safety record with no new safety issues emerging over time. In one study, the rates of serious side effects were lower compared to other treatments, and fewer patients experienced worsening IBD symptoms.

Mirikizumab is unique because it specifically targets the IL-23 protein, which plays a crucial role in the inflammatory processes of inflammatory bowel disease (IBD). Unlike standard treatments like anti-TNF agents and anti-integrin antibodies, which have broader mechanisms, mirikizumab offers a more targeted approach by inhibiting IL-23, potentially reducing inflammation more effectively and with fewer side effects. Researchers are excited because this specificity could lead to better outcomes for patients with ulcerative colitis and Crohn's disease, possibly offering more sustained relief and improved quality of life.

Research has shown that mirikizumab works well for treating inflammatory bowel disease (IBD). In one study, 50.5% of patients had no symptoms after 12 weeks. Another study found that 92.9% of patients remained symptom-free for two years. Long-term studies also demonstrated that mirikizumab kept symptoms away and provided relief for up to four years. In this trial, participants will receive mirikizumab as part of the Mirikizumab Clinical Care Pathway. Meanwhile, another group will receive standard biologic therapies, which may include anti-TNF agents, anti-integrins, IL-12/23 antagonists, or IL-23p19 antagonists. These findings suggest that mirikizumab can effectively manage IBD symptoms and improve patients' quality of life over time.¹²⁶⁷⁸